Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties

Cell Cycle

Volumn 12, Issue 14, 2013, Pages 2183-2193

  Bertero, Thomas ^a,b   Bourget Ponzio, Isabelle ^b,c   Puissant, Alexandre ^b,d   Loubat, Agnès ^b,e   Mari, Bernard ^a,b   Meneguzzi, Guerrino ^b,c   Auberger, Patrick ^b,d   Barbry, Pascal ^a,b   Ponzio, Gilles ^a,e   Rezzonico, Roger ^a,b  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c CNRS   (France)

^d CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^e CENTRE DE BIOCHIMIE   (France)

Author keywords

Apoptosis; Epidermis; MicroRNA; MiR 483 3p; Tumor suppressor

Indexed keywords

MICRORNA; MICRORNA 483 3P; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SQUAMOUS CELL CARCINOMA; TUMOR ENGRAFTMENT; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; XENOGRAFT;

EID: 84880434292     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25330     Document Type: Article

References (72)

1. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9:102-14; PMID:18197166; http://dx.doi.org/10.1038/nrg2290
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66; PMID:17060945; http://dx.doi.org/10.1038/nrc1997 (Pubitemid 44629897)
3. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009; 4:199-227; PMID:18817506; http://dx.doi.org/10.1146/annurev.pathol.4.110807.092222
4. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8; PMID:15944708; http://dx.doi.org/10.1038/nature03702 (Pubitemid 40839735)
5. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482:347-55; PMID:22337054; http://dx.doi.org/10.1038/nature10888
6. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11:849-64; PMID:22113163; http://dx.doi.org/10.1038/nrc3166
7. Haddow A. Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Adv Cancer Res 1972; 16:181-234; PMID:4563044; http://dx.doi.org/10.1016/S0065-230X(08)60341-3
8. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9; PMID:3537791; http://dx.doi.org/10.1056/NEJM198612253152606 (Pubitemid 17052899)
9. Schäfer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008; 9:628-38; PMID:18628784; http://dx.doi.org/10.1038/nrm2455
10. Bertero T, Gastaldi C, Bourget-Ponzio I, Imbert V, Loubat A, Selva E, et al. miR-483-3p controls proliferation in wounded epithelial cells. FASEB J 2011; 25:3092-105; PMID:21676945; http://dx.doi.org/10.1096/fj.10-168401
11. Bertero T, Gastaldi C, Bourget-Ponzio I, Mari B, Meneguzzi G, Barbry P, et al. CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest. Cell Death Differ 2013; 20:800-11; PMID:23429262; http://dx.doi.org/10.1038/cdd.2013.5
12. Kong D, Piao YS, Yamashita S, Oshima H, Oguma K, Fushida S, et al. Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene 2012; 31:3949-60; PMID:22139078; http://dx.doi.org/10.1038/onc. 2011.558
13. Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 2012; 33:1113-20; PMID:22362728; http://dx.doi.org/10.1093/carcin/bgs113
14. Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT. Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2012; 18:5442-53; PMID:23082062; http://dx.doi.org/10.3748/wjg. v18.i38.5442
15. Yi C, Wang Q, Wang L, Huang Y, Li L, Liu L, et al. MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene 2012; 31:4421-33; PMID:22249270; http://dx.doi.org/10.1038/onc.2011.629
16. Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 2010; 70:3140-9; PMID:20388800; http://dx.doi.org/10.1158/0008-5472.CAN-09-4456
17. Özata DM, Caramuta S, Velázquez-Fernández D, Akçakaya P, Xie H, Höög A, et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011; 18:643-55; PMID:21859927; http://dx.doi.org/10.1530/ERC-11-0082
18. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009; 23:2152-65; PMID:19759263; http://dx.doi.org/10.1101/gad.1820109
19. Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer 2009; 48:615-23; PMID:19396864; http://dx.doi.org/10.1002/gcc.20669
20. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, et al. Regulation of insulinlike growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 2010; 70:4666-75; PMID:20484036; http://dx.doi.org/10.1158/0008-5472.CAN-09-3970
21. Yanagida J, Hammiller B, Al-Matouq J, Behrens M, Trempus CS, Repertinger SK, et al. Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin. Carcinogenesis 2012; 33:1754-61; PMID:22764135; http://dx.doi.org/10.1093/carcin/bgs168
22. Shen T, Huang S. The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem 2012; 12:631-9; PMID:22263797; http://dx.doi.org/10.2174/187152012800617678
23. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011; 71:5214-24; PMID:21690566; http://dx.doi.org/10.1158/0008-5472.CAN-10-4645
24. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67:7713-22; PMID:17699775; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-1083 (Pubitemid 47281364)
25. Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008; 118:3714-24; PMID:18949056; http://dx.doi.org/10.1172/JCI34922
26. Pothof J, Verkaik NS, van IJcken W, Wiemer EA, Ta VT, van der Horst GT, et al. MicroRNAmediated gene silencing modulates the UV-induced DNA-damage response. EMBO J 2009; 28:2090-9; PMID:19536137; http://dx.doi.org/10.1038/ emboj.2009.156
27. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ Jr., et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009; 69:8157-65; PMID:19826040; http://dx.doi.org/10.1158/0008-5472. CAN-09-1996
28. Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb- E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev 2009; 23:2388-93; PMID:19833767; http://dx.doi.org/10.1101/gad.1819009
29. Sarkar S, Dey BK, Dutta A. MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A. Mol Biol Cell 2010; 21:2138-49; PMID:20462953; http://dx.doi.org/10.1091/mbc.E10-01-0062
30. Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu N, et al. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res 2010; 1312:120-6; PMID:19948152; http://dx.doi.org/10.1016/j.brainres.2009.11. 056
31. Rissland OS, Hong SJ, Bartel DP. MicroRNA destabilization enables dynamic regulation of the miR-16 family in response to cell-cycle changes. Mol Cell 2011; 43:993-1004; PMID:21925387; http://dx.doi.org/10.1016/j.molcel.2011.08.021
32. Furuta M, Kozaki KI, Tanimoto K, Tanaka S, Arii S, Shimamura T, et al. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One 2013; 8:e60155; PMID:23544130; http://dx.doi.org/10.1371/journal.pone.0060155
33. Marcet B, Chevalier B, Luxardi G, Coraux C, Zaragosi LE, Cibois M, et al. Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol 2011; 13:693-9; PMID:21602795
34. Lizé M, Klimke A, Dobbelstein M. MicroRNA-449 in cell fate determination. Cell Cycle 2011; 10:2874-82; PMID:21857159; http://dx.doi.org/10. 4161/cc.10.17.17181
35. Masyuk T, Masyuk A, LaRusso N. MicroRNAs in cholangiociliopathies. Cell Cycle 2009; 8:1324-8; PMID:19342876; http://dx.doi.org/10.4161/cc.8.9.8253
36. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14:1271-7; PMID:18931683; http://dx.doi.org/10.1038/nm.1880
37. Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, et al. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 2013; 32:976-87; PMID:22469983; http://dx.doi.org/10.1038/onc.2012.121
38. Lizé M, Pilarski S, Dobbelstein M. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ 2010; 17:452-8; PMID:19960022; http://dx.doi.org/10.1038/cdd.2009.188
39. Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C, et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer 2011; 10:29; PMID:21418558; http://dx.doi.org/10.1186/1476- 4598-10-29
40. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010; 70:7027-30; PMID:20807816; http://dx.doi.org/10.1158/ 0008-5472.CAN-10-2010
41. Brezak MC, Valette A, Quaranta M, Contour- Galcera MO, Jullien D, Lavergne O, et al. IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int J Cancer 2009; 124:1449-56; PMID:19065668; http://dx.doi.org/10.1002/ijc.24080
42. Kristjánsdóttir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004; 11:1043-51; PMID:15324805; http://dx.doi.org/10.1016/j. chembiol.2004.07.007 (Pubitemid 39138756)
43. Boutros R, Lobjois V, Ducommun (B) CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7:495-507; PMID:17568790; http://dx.doi.org/10.1038/nrc2169 (Pubitemid 46985396)
44. Hong HY, Choi J, Cho YW, Kim BC. Cdc25A promotes cell survival by stimulating NF-κB activity through IκB-α phosphorylation and destabilization. Biochem Biophys Res Commun 2012; 420:293-6; PMID:22417828; http://dx.doi.org/10.1016/j.bbrc.2012.02.152
45. Dallaglio K, Marconi A, Pincelli (C) Survivin: a dual player in healthy and diseased skin. J Invest Dermatol 2012; 132:18-27; PMID:21900948; http://dx.doi.org/10.1038/jid.2011.279
46. Xia F, Lee CW, Altieri DC. Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res 2008; 68:1826-33; PMID:18339863; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-5279 (Pubitemid 351416568)
47. Barrès V, Ouellet V, Lafontaine J, Tonin PN, Provencher DM, Mes-Masson AM. An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Mol Cancer 2010; 9:272; PMID:20942967; http://dx.doi.org/10.1186/ 1476-4598-9-272
48. Yuen HF, Chan KK, Grills C, Murray JT, Platt- Higgins A, Eldin OS, et al. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res 2012; 18:380-91; PMID:22090358; http://dx.doi.org/10.1158/1078-0432. CCR-11-2035
49. Xia F, Canovas PM, Guadagno TM, Altieri DC. A survivin-ran complex regulates spindle formation in tumor cells. Mol Cell Biol 2008; 28:5299-311; PMID:18591255; http://dx.doi.org/10.1128/MCB.02039-07
50. Viticchiè G, Lena AM, Cianfarani F, Odorisio T, Annicchiarico-Petruzzelli M, Melino G, et al. MicroRNA-203 contributes to skin re-epithelialization. Cell Death Dis 2012; 3:e435; PMID:23190607; http://dx.doi.org/10.1038/cddis.2012.174
51. Tewari M, Yu M, Ross B, Dean C, Giordano A, Rubin R. AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal. Cancer Res 1997; 57:4063-9; PMID:9307294 (Pubitemid 27427698)
52. Rigou P, Piddubnyak V, Faye A, Rain JC, Michel L, Calvo F, et al. The antiapoptotic protein AAC-11 interacts with and regulates Acinus-mediated DNA fragmentation. EMBO J 2009; 28:1576-88; PMID:19387494; http://dx.doi.org/10. 1038/emboj.2009.106
53. Pekow JR, Dougherty U, Mustafi R, Zhu H, Kocherginsky M, Rubin DT, et al. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inf lamm Bowel Dis 2012; 18:94-100; PMID:21557394; http://dx.doi.org/10.1002/ibd.21742
54. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283:13205-15; PMID:18319255; http://dx.doi.org/10.1074/jbc. M707629200
55. Sundaram GM, Common JE, Gopal FE, Srikanta S, Lakshman K, Lunny DP, et al. 'See-saw' expression of microRNA-198 and FSTL1 from a single transcript in wound healing. Nature 2013; 495:103-6; PMID:23395958; http://dx.doi.org/10.1038/ nature11890
56. Sonkoly E, Lovén J, Xu N, Meisgen F, Wei T, Brodin P, et al. MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma. Oncogenesis 2012; 1:e3; PMID:23552555; http://dx.doi.org/10.1038/oncsis.2012.3
57. Elfimova N, Sievers E, Eischeid H, Kwiecinski M, Noetel A, Hunt H, et al. Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration. Biochim Biophys Acta 2013; 1833:1190-8; PMID:23391410; http://dx.doi.org/10.1016/j.bbamcr.2013.01.023
58. Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett 2011; 585:2229-34; PMID:21658389; http://dx.doi.org/10.1016/j.febslet. 2011.05.042
59. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008; 47:1223-32; PMID:18307259; http://dx.doi.org/10.1002/hep.22158 (Pubitemid 351547908)
60. Mallipeddi R. Epidermolysis bullosa and cancer. Clin Exp Dermatol 2002; 27:616-23; PMID:12472531; http://dx.doi.org/10.1046/j.1365-2230.2002.01130.x (Pubitemid 35454216)
61. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66:11590-3; PMID:17178851; http://dx.doi.org/10.1158/ 0008-5472.CAN-06-3613 (Pubitemid 46094168)
62. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26:6133-40; PMID:17404574; http://dx.doi.org/10.1038/sj.onc.1210436 (Pubitemid 47414372)
63. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007; 104:15805-10; PMID:17890317; http://dx.doi.org/10.1073/pnas.0707628104 (Pubitemid 350035380)
64. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009; 10:400-5; PMID:19247375; http://dx.doi.org/10.1038/embor.2009.9
65. Wang Y, Zhang X, Li H, Yu J, Ren X. The role of miRNA-29 family in cancer. Eur J Cell Biol 2013; 92:123-8; PMID:23357522; http://dx.doi.org/10. 1016/j.ejcb.2012.11.004
66. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137:1032-46; PMID:19524507; http://dx.doi.org/10.1016/j. cell.2009.03.047
67. Valastyan S, Weinberg RA. miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 2010; 9:2124-9; PMID:20505365; http://dx.doi.org/10.4161/cc.9.11.11843
68. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010; 120:1298-309; PMID:20237410; http://dx.doi.org/10.1172/JCI39566
69. Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, Wu KJ, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 2010; 70:1635-44; PMID:20145132; http://dx.doi.org/10.1158/0008-5472.CAN-09-2291
70. Gioanni J, Fischel JL, Lambert JC, Demard F, Mazeau C, Zanghellini E, et al. Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol 1988; 24:1445-55; PMID:3181269; http://dx.doi.org/10.1016/ 0277-5379(88)90335-5
71. Magné N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002; 86:1518-23; PMID:11986789; http://dx.doi.org/10.1038/sj.bjc.6600299 (Pubitemid 34548078)
72. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5:1136-44; PMID:16731745; http://dx.doi.org/10.1158/1535-7163.MCT-06-0084 (Pubitemid 43881305)